The influence of kallikrein on the coagulation and the fibrinolytic system depends on the reciprocal activation with factor XII. The inactive prekal1ikrein exists as a single polypeptide chain of 619 amino acids with a molecular weight of 85.000. Activation by factor XII a is achieved by the cleavage of an internal Arg-Ile bond. Plasma kallikrein is then composed of a heavy chain (371 amino acids) and light chain (248 amino acids) held together by disulfide bonds (1, 4, 5, 6). The aminoacid sequence of human plasma prekal1ikrein shows 58% identity with factor XI (2, 3). The heavy chain is composed of repeated sequences homologous to factor XI. The light chain contains the catalytic part of the en- zym and is homologous to the trypsin family of the serine proteases (1). In plasma prekal1ikrein circulates in a complex with high MW kininogen (5). The normal plasma concentration is 50pg/ml. Prekal1ikrein deficiency causes abnormalities in the coagulation, fibrinolytic, complement and kinin systems (7). Several different kallikrein genes are found. The nucleotid sequences show homologies (10). Several DNA polymorphisms in the kallikrein genes are observed (11). The human renal kallikrein and prostate specific antigen (PSA) genes were localized to chromosome 19q13 (8, 9).


Prostate Specific Antigen Band Pattern Single Polypeptide Chain Reciprocal Activation Aminoacid Sequence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chung DW, Fujikawa K, McMullen BA, Davie EW 1986, Biochemistry 25, 2410PubMedCrossRefGoogle Scholar
  2. 2.
    Heimark RL, Davie EW 1979, Biochemistry 18, 5743PubMedCrossRefGoogle Scholar
  3. 3.
    Fujikawa K, Chung DW, Hendrickson LE, Davie EW 1986, Biochemistry 25, 2417PubMedCrossRefGoogle Scholar
  4. 4.
    Wuepper KD, Cochrane CG 1972, J Exp Med 136, 1CrossRefGoogle Scholar
  5. 5.
    Mandle RJ, Colman RW, Kaplan 1976, Proc Natl Acad Sci 11, 4179CrossRefGoogle Scholar
  6. 6.
    Bouma BN, Miles LA, Beretta G, Griffin SH 1980, Biochemistry 19, 1151PubMedCrossRefGoogle Scholar
  7. 7.
    So11o DG, Salem A 1985, Am Clin Lab Sci 15, 279Google Scholar
  8. 8.
    Evans BA et al. 1988, Biochemistry 27, 3124PubMedCrossRefGoogle Scholar
  9. 9.
    Sutherland GR et al. 1988, Cytogenet Cell Genet 48, 205PubMedCrossRefGoogle Scholar
  10. 10.
    Morris BJ 1989, Clin Exp Pharmacol Physiol 16, 345PubMedCrossRefGoogle Scholar
  11. 11.
    Baker AR, Shine J 1985, DNA 4, 445PubMedCrossRefGoogle Scholar
  12. 12.
    Müller-Esterl W, Rauth G, Lottspeich F, Kellermann J, Hen- schen A 1985, Eur J Biochem 149, 15PubMedCrossRefGoogle Scholar
  13. 13.
    Lindahl G, Gersdorf E, Menzel HJ, Duba C, Cleve H, Humphries S, Utermann G 1989, Hum Genet 81, 149PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • H.-J. Leifheit
    • 1
  • H. Cleve
    • 2
  1. 1.Blood Transfusion Service, Bavarian Red CrossMunichGermany
  2. 2.Institute of Anthropology and Human GeneticsUniversity of MunichMunichGermany

Personalised recommendations